NO20065252L - Behandling av forstyrrelser - Google Patents
Behandling av forstyrrelserInfo
- Publication number
- NO20065252L NO20065252L NO20065252A NO20065252A NO20065252L NO 20065252 L NO20065252 L NO 20065252L NO 20065252 A NO20065252 A NO 20065252A NO 20065252 A NO20065252 A NO 20065252A NO 20065252 L NO20065252 L NO 20065252L
- Authority
- NO
- Norway
- Prior art keywords
- disorders
- treatment
- effective amount
- polycondritis
- mammal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Sammendrag Foreliggende oppfinnelse vedrører behandling av polykondritt eller mononeuritis multiplex hos et pattedyr med en effektiv mengde av et antistoff som binder til CD20, eventuelt også med andre midler som behandler slike forstyrrelser i en effektiv mengde.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56322704P | 2004-04-16 | 2004-04-16 | |
US56509804P | 2004-04-22 | 2004-04-22 | |
PCT/US2005/012961 WO2005115453A2 (en) | 2004-04-16 | 2005-04-15 | Treatment of polychondritis and mononeuritis multiplex with anti-cd20 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20065252L true NO20065252L (no) | 2007-01-15 |
Family
ID=35207581
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20065252A NO20065252L (no) | 2004-04-16 | 2006-11-15 | Behandling av forstyrrelser |
Country Status (12)
Country | Link |
---|---|
US (2) | US20060002930A1 (no) |
EP (1) | EP1742660A2 (no) |
JP (1) | JP2007532680A (no) |
AR (1) | AR049021A1 (no) |
AU (1) | AU2005247303A1 (no) |
BR (1) | BRPI0509412A (no) |
CA (1) | CA2562243A1 (no) |
IL (1) | IL178553A0 (no) |
NO (1) | NO20065252L (no) |
RU (1) | RU2006140374A (no) |
TW (1) | TW200603828A (no) |
WO (1) | WO2005115453A2 (no) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7820161B1 (en) * | 1999-05-07 | 2010-10-26 | Biogen Idec, Inc. | Treatment of autoimmune diseases |
MXPA03002262A (es) * | 2000-09-18 | 2003-10-15 | Idec Pharma Corp | Terapia de combinacion para tratamiento de enfermedades autoinmunes usando una combinacion de anticuerpos inmunorreguladores/supresores de celulas b. |
ES2341009T3 (es) * | 2003-11-05 | 2010-06-14 | Roche Glycart Ag | Anticuerpos cd20 con afinidad de union a receptores fc y funcion efectora. |
RU2367667C2 (ru) * | 2004-08-19 | 2009-09-20 | Дженентек, Инк. | Полипептидные варианты с измененной эффекторной функцией |
DOP2006000029A (es) * | 2005-02-07 | 2006-08-15 | Genentech Inc | Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas) |
EP2345412A1 (en) * | 2005-12-02 | 2011-07-20 | The Johns Hopkins University | Use of high-dose oxazaphosphorine drugs for treating immune disorders |
KR20080079301A (ko) * | 2005-12-09 | 2008-08-29 | 시애틀 지네틱스, 인크. | Cd40 결합제를 이용하는 방법 |
US7846724B2 (en) † | 2006-04-11 | 2010-12-07 | Hoffmann-La Roche Inc. | Method for selecting CHO cell for production of glycosylated antibodies |
WO2008034076A2 (en) * | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Cyclophosphamide in combination with immune therapeutics |
WO2008034074A2 (en) | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Cyclosphosphamide in combination with anti-idiotypic vaccines |
WO2008034071A2 (en) | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Method of identifying patients suitable for high-dose cyclophosphamide treatment |
KR20150008503A (ko) | 2007-10-30 | 2015-01-22 | 제넨테크, 인크. | 양이온 교환 크로마토그래피에 의한 항체 정제 |
WO2009067699A2 (en) * | 2007-11-21 | 2009-05-28 | Accentia Biopharmaceuticals, Inc. | Methods for providing a system of care for an oxazaphosphorine drug regimen |
US9026372B2 (en) * | 2007-11-21 | 2015-05-05 | Accentia Biopharmaceuticals, Inc. | Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen |
TW201438738A (zh) | 2008-09-16 | 2014-10-16 | Genentech Inc | 治療進展型多發性硬化症之方法 |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
US8815242B2 (en) * | 2009-05-27 | 2014-08-26 | Synageva Biopharma Corp. | Avian derived antibodies |
AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
DK2493922T3 (en) | 2009-10-26 | 2017-04-24 | Hoffmann La Roche | Process for preparing a glycosylated immunoglobulin |
IN2012DN06309A (no) * | 2010-01-11 | 2015-09-25 | Alexion Pharma Inc | |
BR112012020102A2 (pt) | 2010-02-10 | 2016-11-29 | Immunogen Inc | anticorpos cd20 e usos dos mesmos. |
WO2019126536A1 (en) | 2017-12-20 | 2019-06-27 | Alexion Pharmaceuticals Inc. | Humanized anti-cd200 antibodies and uses thereof |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US93621A (en) * | 1869-08-10 | Improvement in wagon s | ||
US4587A (en) * | 1846-06-20 | Machine for lasting shoes and boots | ||
US128468A (en) * | 1872-07-02 | Improvement in transferring the natural grain of wood | ||
US6404A (en) * | 1849-05-01 | shaw and ezra gould | ||
US103971A (en) * | 1870-06-07 | Improvement in mechanical movement | ||
US136719A (en) * | 1873-03-11 | Improvement in travelers for spinning-rings | ||
US9444A (en) * | 1852-12-07 | Hot-air furnace | ||
US82172A (en) * | 1868-09-15 | Frank stanley | ||
US18041A (en) * | 1857-08-25 | Xwashing-machine | ||
US21781A (en) * | 1858-10-12 | Improved method o f lighting street-lamps by electricity | ||
US147885A (en) * | 1874-02-24 | Improvement in the manufacture of halters and bridles | ||
US133930A (en) * | 1872-12-17 | Improvement in toy spring-guns | ||
US58029A (en) * | 1866-09-11 | Improved window-shade fastening | ||
US25764A (en) * | 1859-10-11 | Improvement in cultivators | ||
US185796A (en) * | 1876-12-26 | Improvement in chairs | ||
US180292A (en) * | 1876-07-25 | Improvement in folding chairs | ||
US9427A (en) * | 1852-11-23 | Whifeletree | ||
US69545A (en) * | 1867-10-08 | curtis | ||
US41847A (en) * | 1864-03-08 | Improved washing-machine | ||
US219818A (en) * | 1879-09-23 | Improvement in evaporating-pans | ||
US88664A (en) * | 1869-04-06 | Improved device tor mowing- away hat | ||
US219433A (en) * | 1879-09-09 | Improvement in grain-binders | ||
US157108A (en) * | 1874-11-24 | Improvement in lubricating compounds | ||
US26801A (en) * | 1860-01-10 | peters | ||
US12665A (en) * | 1855-04-10 | Improvement sssi steam-boilers | ||
US197255A (en) * | 1877-11-20 | Improvement in receivers and stench-traps for street-sewers | ||
US197256A (en) * | 1877-11-20 | Improvement in saw-handles | ||
US965963A (en) * | 1910-03-10 | 1910-08-02 | Harry E Blanchard | Burner for fuel-oils. |
US1156066A (en) * | 1915-06-18 | 1915-10-12 | John W Dupuy | Stove. |
IL47062A (en) * | 1975-04-10 | 1979-07-25 | Yeda Res & Dev | Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde |
US4665077A (en) * | 1979-03-19 | 1987-05-12 | The Upjohn Company | Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds |
US4485045A (en) * | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4544545A (en) * | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4676980A (en) * | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5576195A (en) * | 1985-11-01 | 1996-11-19 | Xoma Corporation | Vectors with pectate lyase signal sequence |
US5618920A (en) * | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
US5567610A (en) * | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
US6893625B1 (en) * | 1986-10-27 | 2005-05-17 | Royalty Pharma Finance Trust | Chimeric antibody with specificity to human B cell surface antigen |
IL85035A0 (en) * | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US4975278A (en) * | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
US5283187A (en) * | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
US4892538A (en) * | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
US5506126A (en) * | 1988-02-25 | 1996-04-09 | The General Hospital Corporation | Rapid immunoselection cloning method |
IL85746A (en) * | 1988-03-15 | 1994-05-30 | Yeda Res & Dev | Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases |
US4861579A (en) * | 1988-03-17 | 1989-08-29 | American Cyanamid Company | Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies |
GB8823869D0 (en) * | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) * | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5208020A (en) * | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5229275A (en) * | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
US5571894A (en) * | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
ATE255131T1 (de) * | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
IE922437A1 (en) * | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
US5587458A (en) * | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
ATE244763T1 (de) * | 1992-02-11 | 2003-07-15 | Cell Genesys Inc | Erzielen von homozygotem durch zielgerichtete genetische ereignisse |
US5573905A (en) * | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
US5736137A (en) * | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
CA2149329C (en) * | 1992-11-13 | 2008-07-15 | Darrell R. Anderson | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
US5595721A (en) * | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
JP3194680B2 (ja) * | 1994-12-15 | 2001-07-30 | 三菱電機株式会社 | 内燃機関の失火検出装置 |
US5731168A (en) * | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5641870A (en) * | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5739277A (en) * | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
US6306393B1 (en) * | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
US6171586B1 (en) * | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
US6368596B1 (en) * | 1997-07-08 | 2002-04-09 | Board Of Regents, The University Of Texas System | Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells |
US6242195B1 (en) * | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
US6528624B1 (en) * | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
US6194551B1 (en) * | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
EP1946775A3 (en) * | 1998-08-11 | 2008-08-06 | Biogen Idec Inc. | Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody |
US6224866B1 (en) * | 1998-10-07 | 2001-05-01 | Biocrystal Ltd. | Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors |
DE19930748C2 (de) * | 1999-07-02 | 2001-05-17 | Infineon Technologies Ag | Verfahren zur Herstellung von EEPROM- und DRAM-Grabenspeicherzellbereichen auf einem Chip |
CA2838062C (en) * | 2001-08-03 | 2015-12-22 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
CN100522999C (zh) * | 2002-02-14 | 2009-08-05 | 免疫医疗公司 | 抗cd20抗体及其融合蛋白和使用方法 |
US20050180972A1 (en) * | 2002-07-31 | 2005-08-18 | Wahl Alan F. | Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders |
US20040032828A1 (en) * | 2002-08-16 | 2004-02-19 | Cellglide Technologies Corp. | Service management in cellular networks |
EP2330130B1 (en) * | 2002-10-17 | 2014-08-27 | Genmab A/S | Human monoclonal antibodies against CD20 |
MXPA05010778A (es) * | 2003-04-09 | 2005-12-12 | Genentech Inc | Terapia para enfermedad autoinmune en un paciente con una respuesta inadecuada a un inhibidor tnf-alfa. |
-
2005
- 2005-04-15 US US11/106,820 patent/US20060002930A1/en not_active Abandoned
- 2005-04-15 CA CA002562243A patent/CA2562243A1/en not_active Abandoned
- 2005-04-15 AU AU2005247303A patent/AU2005247303A1/en not_active Abandoned
- 2005-04-15 WO PCT/US2005/012961 patent/WO2005115453A2/en active Application Filing
- 2005-04-15 BR BRPI0509412-7A patent/BRPI0509412A/pt not_active IP Right Cessation
- 2005-04-15 EP EP05780026A patent/EP1742660A2/en not_active Withdrawn
- 2005-04-15 RU RU2006140374/14A patent/RU2006140374A/ru not_active Application Discontinuation
- 2005-04-15 AR ARP050101492A patent/AR049021A1/es not_active Application Discontinuation
- 2005-04-15 JP JP2007508593A patent/JP2007532680A/ja not_active Withdrawn
- 2005-04-18 TW TW094112278A patent/TW200603828A/zh unknown
-
2006
- 2006-09-26 US US11/535,459 patent/US20070031331A1/en not_active Abandoned
- 2006-10-15 IL IL178553A patent/IL178553A0/en unknown
- 2006-11-15 NO NO20065252A patent/NO20065252L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1742660A2 (en) | 2007-01-17 |
WO2005115453A2 (en) | 2005-12-08 |
CA2562243A1 (en) | 2005-12-08 |
IL178553A0 (en) | 2007-02-11 |
JP2007532680A (ja) | 2007-11-15 |
AU2005247303A1 (en) | 2005-12-08 |
US20060002930A1 (en) | 2006-01-05 |
BRPI0509412A (pt) | 2007-09-04 |
RU2006140374A (ru) | 2008-05-27 |
WO2005115453A3 (en) | 2006-03-16 |
US20070031331A1 (en) | 2007-02-08 |
AR049021A1 (es) | 2006-06-21 |
TW200603828A (en) | 2006-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20065252L (no) | Behandling av forstyrrelser | |
NO20092652L (no) | Konstruert anti-TSLP-antistoff | |
EA200802168A1 (ru) | Гуманизированное антитело к с-kit | |
NO20091926L (no) | Anti-Notch3-agonist-antistoffer og deres anvendelse ved behandlingen av Notch3-relaterte sykdommer | |
PH12015500248A1 (en) | Humanized anti-cxcr5 antibodies, derivatives thereof and their uses | |
ECSP088451A (es) | Anticuerpos antagonistas dirigidos contra el péptido relacionado con el gen de calcitonina y métodos que los usan | |
NO20061412L (no) | Terapi av okulaere foretyrrelser | |
ATE469658T1 (de) | Kombinationstherapien gegen multiple toll-like- rezeptoren und ihre verwendung | |
NO20092718L (no) | Antagonist-anti-Notch 3-antistoffer og deres anvendelse i forebyggelsen og behandlingen av Notch 3-relaterte sykdommer | |
ATE469895T1 (de) | Cgrp-rezeptorantagonisten | |
EA200970556A1 (ru) | Моноклональные антитела против angptl3 | |
MA35740B1 (fr) | Compositions et procédés pour des anticorps ciblant le facteur p | |
NO20075845L (no) | Fremgangsmate for behandling av inflammatorisk tarmsykdom (IBD) med et anti-CD20-antistoff | |
EA200401198A1 (ru) | АНТИТЕЛА ПРОТИВ αvβ6 | |
WO2006122257A3 (en) | Nebulization of monoclonal antibodies for treating pulmonary diseases | |
CL2007002800A1 (es) | Anticuerpo monoclonal anti-receptor a de interleucina 17 (il-17ra) o fragmento de union a antigeno del mismo; polinucleotido que lo codifica; metodo de preparacion; y metodo para tratar un trastorno influido por la activacion de il-17ra. | |
EA200900831A1 (ru) | Модуляторы никотиновых ацетилхолиновых рецепторов | |
MA39061A1 (fr) | Modulateurs d'aplnr et leurs utilisations | |
NO20074238L (no) | Fiksert dosering av HER-antistoffer | |
MX2009008104A (es) | Hepcidina, antagonistas de hepcidina y metodos de uso. | |
MY151191A (en) | Novel antibodies | |
EA201000717A1 (ru) | Молекулы и способы, предназначенные для модуляции компонента системы комплемента | |
UA99292C2 (uk) | Антитіло, яке специфічно зв'язується з нейропіліном-2в (nrp2b) | |
DK1987357T3 (da) | Polypeptider, som genkendes af anti-Trichinella-antistoffer, og anvendelser deraf | |
MX2021016098A (es) | Moleculas de anticuerpos humanizados contra cd138 y usos de las mismas. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |